MAP2K7 and metastatic melanoma: The second dataset (GSE61992, Long et al.)included 10 patients with BRAF-mutant metastatic melanoma that were treated with a combination of dabrafenib and the MEK inhibitor (MEKi) trametinib and evaluated for RECIST response and PFS [17].